BioCryst Pharmaceuticals (BCRX) Earnings Analysis
BioCryst Pharmaceuticals (BCRX) next reports earnings on 2026-08-03, consensus EPS 0.14 USD. Last quarter (2026-02-26) it beat with EPS 1.12 USD vs 0.07 USD est (+1500%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -5.50.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BCRX next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | 0.14 USD |
| Revenue estimate | 0.18B |
BCRX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | 1.12 USD | 0.07 USD | +1500% | Beat |
| 2025-11-03 | 0.06 USD | 0.07 USD | -14.3% | Miss |
| 2025-08-04 | 0.15 USD | 0.03 USD | +400% | Beat |
| 2025-05-05 | 0.00015 USD | -0.07 USD | +100.2% | Beat |
| 2025-02-24 | -0.13 USD | -0.07 USD | -85.7% | Miss |
| 2024-11-04 | -0.07 USD | -0.07 USD | 0% | Beat |
| 2024-08-05 | -0.06 USD | -0.19 USD | +68.4% | Beat |
Beat rate: 5/7 (71%) over reported quarters with consensus data.
BCRX valuation and analyst view
| Trailing P/E | -5.50 |
|---|---|
| Trailing EPS | -1.89048 USD |
| Price / book | -4.16 |
| Dividend yield | 0.00% |
| Market cap | 1.99B |
| Analyst consensus | Buy (25 buy / 4 hold / 0 sell) |
| Avg price target | 20 USD |
Related research pages
Frequently asked questions
When is BioCryst Pharmaceuticals (BCRX)'s next earnings date?
BioCryst Pharmaceuticals is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 0.14 USD and revenue estimate of 0.18B.
Did BCRX beat earnings last quarter?
In its 2026-02-26 report, BCRX posted EPS of 1.12 USD versus a 0.07 USD estimate — a beat of 1500%.
What is BCRX's earnings track record?
Over the last 7 reported quarters with consensus data, BCRX beat estimates 5 times (71%).
What is BCRX's current P/E ratio and EPS?
BCRX trades at a trailing P/E of -5.50 on trailing EPS of -1.8904762691015364 USD.
What do analysts rate BCRX?
Analyst consensus is "Buy" across 29 ratings (0 strong buy, 25 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 20 USD.